Clinical experience of ingenol mebutate gel for the treatment of Bowen's disease

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There are only a few anecdotal case reports about Bowen's disease (BD) treated with ingenol mebutate (IM) gel but no clinical study has been published yet. The aim of this study was to evaluate the effectiveness of IM gel in the treatment of BD and to observe the therapeutic efficacy of IM alone or IM with ablative fractional laser pretreatment. Nineteen patients with BD or squamous cell carcinoma in situ confirmed by skin biopsy were enrolled. IM was applied with 0.015% gel on facial lesions for 3 days consecutively and 0.05% gel on other sites for 2 days consecutively, with a 5-mm application margin around the visible lesion. Nine patients applied IM gel immediately following fractional CO2 laser treatment. Two patients were lost to follow up and a total of 17 patients were enrolled. Nine patients (9/17, 52.9%) had a clinically complete response at 2 months after treatment. Among the patients treated with the fractional CO2 laser before applying IM gel, eight (8/9, 88.9%) showed a complete response and one (1/9, 11.1%) showed partial response. Among the patients treated with IM gel alone, only one patient (1/8, 12.5%) showed a complete response, four (4/8, 50%) showed a partial response and three (3/8, 37.5%) did not respond to therapy. IM gel alone seems to have limited value for treatment of BD; however, a combination therapy with the ablative fractional laser can increase its therapeutic effectiveness.

Original languageEnglish
Pages (from-to)425-430
Number of pages6
JournalJournal of Dermatology
Volume45
Issue number4
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Bowen's Disease
Gels
Therapeutics
Gas Lasers
Lasers
3-ingenyl angelate
Lost to Follow-Up
Carcinoma in Situ
Squamous Cell Carcinoma
Biopsy

Keywords

  • Bowen's disease
  • fractional laser
  • ingenol mebutate
  • laser-assisted drug delivery
  • squamous cell carcinoma in situ

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical experience of ingenol mebutate gel for the treatment of Bowen's disease. / Lee, Dong Won; Ahn, Hyo Hyun; Kye, Young Chul; Seo, Soo-Hong.

In: Journal of Dermatology, Vol. 45, No. 4, 01.04.2018, p. 425-430.

Research output: Contribution to journalArticle

@article{e41735f501a240dea72e238396c4e313,
title = "Clinical experience of ingenol mebutate gel for the treatment of Bowen's disease",
abstract = "There are only a few anecdotal case reports about Bowen's disease (BD) treated with ingenol mebutate (IM) gel but no clinical study has been published yet. The aim of this study was to evaluate the effectiveness of IM gel in the treatment of BD and to observe the therapeutic efficacy of IM alone or IM with ablative fractional laser pretreatment. Nineteen patients with BD or squamous cell carcinoma in situ confirmed by skin biopsy were enrolled. IM was applied with 0.015{\%} gel on facial lesions for 3 days consecutively and 0.05{\%} gel on other sites for 2 days consecutively, with a 5-mm application margin around the visible lesion. Nine patients applied IM gel immediately following fractional CO2 laser treatment. Two patients were lost to follow up and a total of 17 patients were enrolled. Nine patients (9/17, 52.9{\%}) had a clinically complete response at 2 months after treatment. Among the patients treated with the fractional CO2 laser before applying IM gel, eight (8/9, 88.9{\%}) showed a complete response and one (1/9, 11.1{\%}) showed partial response. Among the patients treated with IM gel alone, only one patient (1/8, 12.5{\%}) showed a complete response, four (4/8, 50{\%}) showed a partial response and three (3/8, 37.5{\%}) did not respond to therapy. IM gel alone seems to have limited value for treatment of BD; however, a combination therapy with the ablative fractional laser can increase its therapeutic effectiveness.",
keywords = "Bowen's disease, fractional laser, ingenol mebutate, laser-assisted drug delivery, squamous cell carcinoma in situ",
author = "Lee, {Dong Won} and Ahn, {Hyo Hyun} and Kye, {Young Chul} and Soo-Hong Seo",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/1346-8138.14240",
language = "English",
volume = "45",
pages = "425--430",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Clinical experience of ingenol mebutate gel for the treatment of Bowen's disease

AU - Lee, Dong Won

AU - Ahn, Hyo Hyun

AU - Kye, Young Chul

AU - Seo, Soo-Hong

PY - 2018/4/1

Y1 - 2018/4/1

N2 - There are only a few anecdotal case reports about Bowen's disease (BD) treated with ingenol mebutate (IM) gel but no clinical study has been published yet. The aim of this study was to evaluate the effectiveness of IM gel in the treatment of BD and to observe the therapeutic efficacy of IM alone or IM with ablative fractional laser pretreatment. Nineteen patients with BD or squamous cell carcinoma in situ confirmed by skin biopsy were enrolled. IM was applied with 0.015% gel on facial lesions for 3 days consecutively and 0.05% gel on other sites for 2 days consecutively, with a 5-mm application margin around the visible lesion. Nine patients applied IM gel immediately following fractional CO2 laser treatment. Two patients were lost to follow up and a total of 17 patients were enrolled. Nine patients (9/17, 52.9%) had a clinically complete response at 2 months after treatment. Among the patients treated with the fractional CO2 laser before applying IM gel, eight (8/9, 88.9%) showed a complete response and one (1/9, 11.1%) showed partial response. Among the patients treated with IM gel alone, only one patient (1/8, 12.5%) showed a complete response, four (4/8, 50%) showed a partial response and three (3/8, 37.5%) did not respond to therapy. IM gel alone seems to have limited value for treatment of BD; however, a combination therapy with the ablative fractional laser can increase its therapeutic effectiveness.

AB - There are only a few anecdotal case reports about Bowen's disease (BD) treated with ingenol mebutate (IM) gel but no clinical study has been published yet. The aim of this study was to evaluate the effectiveness of IM gel in the treatment of BD and to observe the therapeutic efficacy of IM alone or IM with ablative fractional laser pretreatment. Nineteen patients with BD or squamous cell carcinoma in situ confirmed by skin biopsy were enrolled. IM was applied with 0.015% gel on facial lesions for 3 days consecutively and 0.05% gel on other sites for 2 days consecutively, with a 5-mm application margin around the visible lesion. Nine patients applied IM gel immediately following fractional CO2 laser treatment. Two patients were lost to follow up and a total of 17 patients were enrolled. Nine patients (9/17, 52.9%) had a clinically complete response at 2 months after treatment. Among the patients treated with the fractional CO2 laser before applying IM gel, eight (8/9, 88.9%) showed a complete response and one (1/9, 11.1%) showed partial response. Among the patients treated with IM gel alone, only one patient (1/8, 12.5%) showed a complete response, four (4/8, 50%) showed a partial response and three (3/8, 37.5%) did not respond to therapy. IM gel alone seems to have limited value for treatment of BD; however, a combination therapy with the ablative fractional laser can increase its therapeutic effectiveness.

KW - Bowen's disease

KW - fractional laser

KW - ingenol mebutate

KW - laser-assisted drug delivery

KW - squamous cell carcinoma in situ

UR - http://www.scopus.com/inward/record.url?scp=85045830068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045830068&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.14240

DO - 10.1111/1346-8138.14240

M3 - Article

C2 - 29383745

AN - SCOPUS:85045830068

VL - 45

SP - 425

EP - 430

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 4

ER -